Denali Therapeutics Inc (NASDAQ:DNLI) has earned a consensus rating of “Hold” from the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $24.00.
A number of analysts have recently weighed in on DNLI shares. ValuEngine upgraded Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research lowered Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.
Large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in shares of Denali Therapeutics in the first quarter valued at $20,753,000. Goldman Sachs Group Inc. acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at $2,189,000. Baillie Gifford & Co. increased its stake in shares of Denali Therapeutics by 5.5% in the first quarter. Baillie Gifford & Co. now owns 5,192,846 shares of the company’s stock valued at $102,247,000 after buying an additional 271,063 shares in the last quarter. Northern Trust Corp acquired a new stake in shares of Denali Therapeutics in the first quarter valued at $3,309,000. Finally, Wells Fargo & Company MN acquired a new stake in shares of Denali Therapeutics in the fourth quarter valued at $621,000. Institutional investors own 64.00% of the company’s stock.
Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 9th. The company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.39). The firm had revenue of $1.65 million during the quarter, compared to the consensus estimate of $3.00 million. equities analysts anticipate that Denali Therapeutics will post -0.74 EPS for the current fiscal year.
About Denali Therapeutics
Denali Therapeutics, Inc engages in the development of portfolio of therapeutic candidates for neurodegenerative diseases. Its programs comprises of lysosomal function pathway, glial biology pathway, and cellular homeostasis. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth in 2013 and is headquartered in San Francisco, CA.
Featured Story: Market Capitalization in the Stock Market
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.